IL-15/sIL-15Rα gene transfer suppresses Lewis lung cancer growth in the lungs, liver and kidneys
Authors:
- 8 January 2016
- journal article
- research article
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 23 (2-3) , 54-60
Abstract
Nearly 40% of people with lung cancer have tumor growth in other organs at the time of diagnosis. Current treatment strategies for patients with late-stage lung cancer are primarily palliative and only showed modest efficacy. The current study takes advantage of the hydrodynamic gene delivery technique to evaluate the antitumor activity of interleukin (IL)-15/sIL-15Rα on lung tumors growing in the lungs, liver and kidneys. We demonstrate that hydrodynamic tail vein injection of 2 μg of AG209 DP muIL-15sRα+IL-15 plasmid resulted in serum IL-15/sIL-15Rα reaching a peak level of ~10 μg ml−1 1 day after the injection and gradually declined to ~5 ng ml−1 within 3 days. Quantitative PCR analysis revealed that overexpression of IL-15/sIL-15Rα induced the activation of natural killer and T cells, evidenced by increased mRNA levels of marker genes including granzyme B, perforin, Ifn-γ, T-bet and Cd8 in the lungs, liver and kidneys. Importantly, transfer of the Il-15/sIl-15Rα gene alone, or in combination with gemcitabine chemotherapy, significantly inhibited the tumor growth in these three organs and prolonged median survival time of treated mice by 1.7- and 3.3-fold, respectively. The therapeutic benefits are principally blockade and elimination of tumor growth in the liver and kidneys. Taken together, these results suggest that IL-15/sIL-15Rα-based gene therapy could be an effective approach to treat late-stage lung cancer with metastases in other organs.Keywords
This publication has 31 references indexed in Scilit:
- Interleukin-15 biology and its therapeutic implications in cancerTrends in Pharmacological Sciences, 2012
- Hydrodynamic cell delivery for simultaneous establishment of tumor growth in mouse lung, liver and kidneyCancer Biology & Therapy, 2011
- Interleukin-15 and Its Receptor Augment Dendritic Cell Vaccination against theneuOncogene through the Induction of Antibodies Partially Independent of CD4 HelpCancer Research, 2010
- American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2009
- Myeloid-derived suppressor cells as regulators of the immune systemNature Reviews Immunology, 2009
- Interleukin-15/Interleukin-15Rα Complexes Promote Destruction of Established Tumors by Reviving Tumor-Resident CD8+ T CellsCancer Research, 2008
- Efficient Systemic Expression of Bioactive IL-15 in Mice upon Delivery of Optimized DNA Expression PlasmidsDNA and Cell Biology, 2007
- The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine designNature Reviews Immunology, 2006
- Converting IL-15 to a superagonist by binding to soluble IL-15RαProceedings of the National Academy of Sciences, 2006
- Cytokines in cancer immunity and immunotherapyImmunological Reviews, 2004